Nebenwirkungen · NovoSeven
NovoSeven 1 mg (50 KIU) powder and solvent for solution for injection NovoSeven 2 mg (100 KIU) powder and solvent for solution for injection NovoSeven 5 mg (250 KIU) powder and solvent for solution for injection NovoSeven 8 mg (400 KIU) powder and solvent for solution for injection · Abschnitt 4.8 · PDF-Seite 7
HOS-085100 · Präparat HOS-083079
Clinical trials conducted in 484 patients (including 4297 treatment episodes) with haemophilia A and B, acquired haemophilia, factor VII deficiency or Glanzmann’s thrombasthenia have shown that adverse drug reactions are common (≥ 1/100 to < 1/10). As the total number of treatment episodes in clinical trials is below 10,000, the lowest possible frequency of adverse drug reactions that can be assigned is rare (≥ 1/10,000 to < 1/1,000).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-01-05T10:11:00Z · SHA-256 4cde9b1f299068eba5f867a596fb73966c9f4132d6fc783820f32def35917cf3 · Passage 799abfcfae6ca27e21728138bd348dace189afc3931a8ca7bad8bb9ff9167a45 · Zeichen 635–1073 im Abschnitt